Wound Healing News and Research

RSS

Cellular and subcellular effects of PACE technology presented

SANUWAVE Health, Inc., (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, announced that the cellular and subcellular effects of PACE™ technology were described during a lecture presented this past weekend.

15 Dec 2009

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

ProChon Biotech, Ltd., an innovator of tissue regenerative technologies that are being developed to relieve pain and restore the mobility and quality of life for sufferers of articular cartilage injuries, today announced a significant expansion of its clinical study of the BioCart™ Cartilage Regeneration System.

15 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

Proteins from catfish venom glands could accelerate wound healing in humans

Lest anyone have concerns about attacks of killer catfish, rest assured that, at least in North America, these finned fatales use their venom mainly to defend themselves against predatory fish, though they can inflict a painful sting that many fishermen have suffered. In other parts of the world, some catfish do have extremely toxic venoms that can be deadly to humans.

11 Dec 2009

Latest findings on how blood clots form can open door to the development of new drugs

The latest findings on how blood clots form could open the door to the development of new and better-targeted drugs for patients at risk of strokes or heart attacks.

11 Dec 2009

BIOGUARD barrier gauze dressings offer high antiviral efficacy against H1N1

Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a specialty medical device and pharmaceutical company focused on advanced wound care, today released an independent laboratory report indicating that the company's BIOGUARD barrier gauze dressings exhibit high antiviral efficacy against the H1N1 virus.

10 Dec 2009

Dermal stem cells may be useful for treating diabetic ulcers and neurological disorders

Scientists have discovered a new type of stem cell in the skin that acts surprisingly like certain stem cells found in embryos: both can generate fat, bone, cartilage, and even nerve cells.

10 Dec 2009

RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352

REGENERX BIOPHARMACEUTICALS, INC. announced today that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. The trial included testing of a single escalating intravenous dose of the drug candidate on forty healthy volunteers in Phase IA and, subsequently, over a fourteen-day treatment period on forty volunteers in Phase IB.

9 Dec 2009

BIOGUARD barrier gauze dressings exhibit high antiviral efficacy against H1N1 virus

An independent lab report demonstrated that BIOGUARD™ barrier gauze dressings exhibit greater than 99.9% inactivation rates against swine flu virus after exposure for 24 hours.

8 Dec 2009

Researchers identify gene expression and biological pathways for healing gingivitis

Gingivitis, which may affect more than one-half of the U.S. adult population, is a condition commonly attributed to lapses in simple oral hygiene habits. However, a new study shows that development and reversal of gingivitis at the molecular level is apparently much more complicated than its causes might indicate.

8 Dec 2009

Absorption Systems opens renovated AAALAC-accredited GLP surgical suite for medical device testing

Absorption Systems, a leader in testing drugs for ADMET (absorption, distribution, metabolism, excretion and toxicity), today introduced an extensively renovated surgical suite for preclinical medical device testing at the company’s facility in San Diego, CA. Absorption Systems has long been recognized as a leader in drug testing and is experiencing increased demand for its medical device testing services as well.

4 Dec 2009

PRP shows strong potential for accelerated healing of dental implant procedures

An exciting treatment gaining acceptance in orthopedics and sports medicine, called platelet-rich plasma therapy (PRP), is showing strong potential for accelerated healing of dental implant procedures, according to a prominent dental researcher and editor of the Journal of Oral Implantology.

4 Dec 2009

Tripep receives approval to extend ChronVac-C study

Today Tripep (STO:TPEP) received the approval from the Swedish Medical Products Agency and the local ethical committee to give three patients in the highest dose group in the ChronVac-C® study one additional treatment with the therapeutic vaccine.

3 Dec 2009

Exercise remains one of the most effective interventions for peripheral artery disease

Peripheral artery disease (PAD) affects 5 million individuals in the U.S. and is the leading cause of limb amputations. Doctors have long considered exercise to be the single best therapy for PAD, and now a new study helps explain why. Led by researchers at Beth Israel Deaconess Medical Center and published in this week's Online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), the findings demonstrate that a protein called PGC-1alpha plays a key role in the process.

3 Dec 2009

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

DermaGen AB - part of the Karolinska Development dermatology and wound healing company "Pergamum" - announced that Dermagen AB has received promising results from a clinical Phase I/IIa study. DermaGen AB is developing a novel antimicrobial peptide (AMP) treatment for atopic dermatitis. Atopic dermatitis is a chronic inflammatory skin disease where dry skin and the skin's weakened barrier function make patients susceptible to colonization by microorganisms, a triggering or exacerbating factor of the disease.

2 Dec 2009

Study provides new insight into the mechanism of bacterial invasion protein

Spoiled meat is one of the sources for Listeria infections leading to listeriosis. Pregnant women, newborns and immune compromised people are susceptible for a severe progression of this disease. Firstly, the pathogen breaches the intestinal barrier and thus enters the body. The key for further spreading is the invasion protein internalin B that is located on the bacterial surface.

30 Nov 2009

Rights Issue to be carried out by keeping the authorization by the Annual General Meeting, resolves Tripep

The Board of Directors of Tripep AB (publhas on the 27th of November 2009, based on the authorization by the Annual General Meeting resolved to carry out a rights issue.

27 Nov 2009

Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment

All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep’s therapeutic vaccine ChronVac-C have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus.

27 Nov 2009

Advitech announces merger operations with Botaneco Specialty Ingredients

Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announced today that, further to the consolidation of its common shares on a 8-for-1 basis (the "Consolidation"), the TSX Venture Exchange Inc. (the "TSX-V") has approved the release from escrow of the previously announced acquisition of all the issued and outstanding shares of Botaneco Specialty Ingredients Inc.

27 Nov 2009

TSX Venture Exchange approves Advitech's issued and outstanding common shares

Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announced today that the TSX Venture Exchange Inc. (the "TSX-V") approved the previously announced consolidation of its issued and outstanding common shares on the basis of a ratio of eight pre-Consolidation shares for every one post-Consolidation share (the "Consolidation") and that the common shares of Advitech will be traded on a post-Consolidation basis starting November 26, 2009.

26 Nov 2009

Wound Healing News and Research

Cellular and subcellular effects of PACE technology presented

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Proteins from catfish venom glands could accelerate wound healing in humans

Latest findings on how blood clots form can open door to the development of new drugs

BIOGUARD barrier gauze dressings offer high antiviral efficacy against H1N1

Dermal stem cells may be useful for treating diabetic ulcers and neurological disorders

RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352

BIOGUARD barrier gauze dressings exhibit high antiviral efficacy against H1N1 virus

Researchers identify gene expression and biological pathways for healing gingivitis

Absorption Systems opens renovated AAALAC-accredited GLP surgical suite for medical device testing

PRP shows strong potential for accelerated healing of dental implant procedures

Tripep receives approval to extend ChronVac-C study

Exercise remains one of the most effective interventions for peripheral artery disease

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

Study provides new insight into the mechanism of bacterial invasion protein

Rights Issue to be carried out by keeping the authorization by the Annual General Meeting, resolves Tripep

Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment

Advitech announces merger operations with Botaneco Specialty Ingredients

TSX Venture Exchange approves Advitech's issued and outstanding common shares

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News